-
Continue reading →: #64 ❤️🩹 Healthspan vs Lifespan The Future of Longevity with CytonicsMost people talk about lifespan. We obsess over how long we live. What actually matters is healthspan.How long we stay strong, mobile, and pain-free. Living to 90 means very little if your joints fail you at 60. At Cytonics Corporation, our mission is simple: extend healthspan by protecting the biology… read more
-
Continue reading →: #63 🌱 Don’t Plant Seeds in a Firestorm: Why Recent Stanford Article Validates Cytonics DMOAD ApproachYou may have seen the recent headlines regarding a breakthrough in “anti-aging injections” for cartilage regeneration, published in Science (Singla et al., 2025). Led by Stanford Medicine, this research identifies the inhibition of 15-hydroxyprostaglandin dehydrogenase (15-PGDH) as a novel pathway to restore regenerative capacity in chondrocytes (the cartilage-secreting cells in… read more
-
Continue reading →: #62 🙏 Another Year Full of Gratitude
As the year concludes, Joey Bose reflects on gratitude towards investors, the Cytonics community, and the dedicated team. He emphasizes the importance of long-term commitment and support in their progress. Looking ahead to 2026, he encourages everyone to cherish time with loved ones and appreciate their contributions. read more
-
Continue reading →: #61 🛑 Can We Stop Osteoarthritis Before It Starts?Some individuals inherit a genetic risk for osteoarthritis, potentially experiencing severe symptoms by their 40s or 50s. Early identification and treatment with alpha-2-macroglobulin (A2M) may preserve joint health and enhance quality of life. Development of CYT-108 aims to target the root cause of osteoarthritis, rather than just alleviate pain. read more
-
Continue reading →: #60 👎 Where Big Pharma Tried And FailedOsteoarthritis (OA) is a major global issue, costing $393 billion with no effective treatments. Big Pharma’s efforts have failed due to targeting single enzymes and poor drug design. Cytonics offers a multi-target approach with CYT-108, directly applied to joints and leveraging proven methods, aiming for successful Phase 2 trials. read more
-
Continue reading →: #59 🧬 Why is A2M being called a physiological guardian?
Joey Bose, our CEO and President, breaks down why researchers have called A2M the ‘physiological guardian.’ A2M, or alpha-2-macroglobulin, is a natural protein found in your bloodstream that acts like a bodyguard against inflammation and joint destruction. It works as a broad-spectrum protease inhibitor and also sequesters cytokines – the… read more
-
Continue reading →: #58 🚅 Inside the Engine Room: Progress Since Our $7M RaiseHow Cytonics is preparing for its next regulatory milestone — from database lock to FDA engagement. It’s been just over a month since we wrapped up our $7M crowdfunding campaign — our largest and most successful raise to date — and the pace hasn’t slowed for a moment. Since then,… read more
-
Continue reading →: #57: 👎 Why Cytonics Turned Down VCCytonics rejects venture capital, believing it stifles innovation and dilutes shareholder value. Instead, they rely on over $25 million raised from individual investors who prioritize genuine progress over quick exits. With a strong community of 7,000 shareholders, they emphasize equity crowdfunding as a pathway to democratized and collaborative biotech advancement. read more
-
Continue reading →: #56 🚗 Our CEO Delivers A Quick Message From the Road!The message emphasizes gratitude towards patients and investors who contribute to Cytonics’ mission. Highlighting milestones like treating over 10,000 patients and issuing 25 patents, it reinforces that Cytonics is community-driven and not just a typical biotech firm. The team appreciates all stakeholders and encourages further investment. read more
-
Continue reading →: #55 🧬 Perfecting Nature’s BlueprintCytonics has developed CYT-108, a refined version of the naturally occurring protein Alpha-2-Macroglobulin (A2M), to combat osteoarthritis. By optimizing A2M for enhanced protease inhibition, the precision-engineered biologic minimizes side effects and maximizes therapeutic potential. It’s backed by extensive scientific validation and patented for patient safety and efficacy. read more
Hello,
I’m Joey Bose, CEO of Cytonics
I started this blog to track our drug development journey as we take on the Boogeyman of regenerative medicine – osteoarthritis (OA). If successful, we will have developed the first and only “true” disease-modifying treatment for OA, succeeding where Big Pharma has repeatedly failed, and forever changing the lives of 600M suffering people worldwide. And if that wasn’t enough, we will have done so without a dime of Venture Capital or institutional support. Cytonics is a company For the People, By the People, and we are extremely proud of our grassroots approach to biopharmceutical development! Want to get involved? invest.cytonics.com